CME/CE Podcast - Integrating TROP2-Directed ADCs into TNBC Treatment Plans: Novel Aspects of Efficacy and Safety Profiles

About this episode

This CME/CE-certified podcast provides an update on TROP2-directed ADCs in treating metastatic triple-negative breast cancer.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/the-evolving-role-of-antibody-drug-conjugates-in-metastatic-triple-negative-breast-cancer-10800 Summary This CME/CE-certified podcast will provide multidisciplinary clinicians with an evidence-based update on the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline treatment of metastatic triple-negativ...

Topics covered

• TROP2-directed ADCs
• triple-negative breast cancer
• CME/CE education
• treatment plans
• efficacy and safety profiles

Keywords

• CME
• CE
• TROP2
• ADCs
• triple-negative breast cancer
• treatment
• efficacy
• safety

Mentioned in this episode

Organizations: NACE

Products: TROP2-directed antibody-drug conjugates

Books & works: CME/CE-certified podcast

Places: metastatic triple-negative breast cancer

More episodes of The NACE Clinical Highlights Show

• NACE Journal Club #31 · June 1, 2026 · 31 min
• NACE Journal Club #30 · May 1, 2026 · 26 min
• NACE Journal Club #29 · April 1, 2026 · 34 min
• APAPP 2026 GOLD Guidelines · April 1, 2026 · 36 min
• APAPP Refractory Chronic Cough · April 1, 2026 · 39 min
• NACE Journal Club #28 · March 1, 2026 · 35 min